Fuji Pharma Co.,Ltd. (4554) Stock Price

Fuji Pharmaceutical Industries Co., Ltd. is primarily engaged in the research and development, manufacturing, and sales of pharmaceutical products, together with one consolidated subsidiary. The company operates mainly in injectable medications and maintains an integrated value chain for pharmaceutical products.

The company's primary customers are medical institutions and wholesale distributors, with product sales serving as the core revenue source. Operating five locations nationwide, the company focuses on domestic sales while also conducting product sales, purchases, and loan transactions with OLIC (Thailand) Limited.

The company's product portfolio centers on hormone injectable medications used in obstetrics and gynecology, and contrast injectable medications for urography and angiography used in radiology. The business consists of a single pharmaceutical segment, and segment-specific disclosures are not provided.

The company aims to achieve net sales of 80 billion yen and operating profit of 10 billion yen in the fiscal year ending September 2029, the final year of its medium-term management plan. Operating profit margin is targeted to improve from 8.4% in fiscal year ending September 2024 to 12.5%, EBITDAR is expected to double from 10.6 billion yen to 23 billion yen, earnings per share on an operating profit basis is targeted at 240 yen, and ROE is targeted at 10%. To achieve these numerical targets, the company has identified four strategic pillars: women's health, biosimilars, global contract development and manufacturing (CDMO), and strategic investments for future growth.

The company has positioned women's health as its priority investment area. Centered on Alissa Combination Tablets, launched in December 2024, the company is pursuing market penetration through products such as F-Meno Capsule and oral contraceptives. Based on the domestic market size for menstruation-related and menopausal conditions and unmet medical needs, the company has deployed 90 dedicated medical representatives in women's health to strengthen physician engagement and is advancing the use of a physician platform (M3). In the biosimilar business, the company plans to expand its product lineup by obtaining approval for three additional products in September 2025, in addition to its existing three products, aiming to accelerate market adoption while maintaining quality standards.

As concrete measures for business expansion, the company is targeting expanded distribution in ASEAN markets centered on production bases in Japan and Thailand, as well as increased contract manufacturing orders in global CDMO operations. Through collaboration between Thailand's OLIC and the Toyama plant, diverse dosage forms can be produced. As a geopolitically stable hub, the company aims to secure contract manufacturing projects from Western companies. The contract development and manufacturing market is expected to grow at an average annual rate of approximately 7.2%, and the company will strengthen its revenue base by focusing on stable supply, enhanced production efficiency, and lifecycle management of marketed products.

The company is also investing in technological innovation and organizational strengthening, planning to establish a corporate venture capital fund and research hubs in North America and Europe to strengthen early-stage drug discovery. The company will also establish a dedicated digital organization to promote AI and data utilization, advancing research and development capabilities and supply chain sophistication. On the human resources front, the company is creating a more inclusive workplace for women and raising the percentage of female managers from the current 20%, pursuing sustainable growth through organizational culture reform.